Gut 2007;56:390-395
HEPATITIS
Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy
1 Service d’Hépatologie and INSERM CRB3, University of Paris VII, AP-HP Hôpital Beaujon, Clichy, France
2 Service d’Anatomie Pathologique, AP-HP Hôpital Beaujon, Clichy, France
3 Département d’Epidemiologie, Biostatistique et Recherche Clinique, AP-HP Hôpital Bichat, Paris, France
4 Service de Biochimie, AP-HP Hôpital Beaujon, Clichy, France
5 Hepatology Unit of University of Bahia, Brazil
Correspondence to:
Professor Patrick Marcellin
Service d’Hépatologie, Hôpital Beaujon, 100 Bd du Gl Leclerc, 92110 Clichy, France; patrick.marcellin{at}bjn.ap-hop-paris.fr
Background and aims: The rates of fibrosis progression in chronic hepatitis C are significantly different between males and females. The antifibrogenic effect of oestrogen has been proposed, possibly via inhibition of stellate cells. The aim of this study was to evaluate the severity of chronic hepatitis C in women, in relation to the menopause, steatosis and hormone replacement therapy (HRT).
Methods: From November 2003 to October 2004, women with chronic hepatitis C were enrolled prospectively. A questionnaire was completed prospectively and a blood sample was obtained on the day of biopsy. We identified characteristics associated with moderate/severe fibrosis using univariate and multivariate analysis.
Results: 251 women were included in the study. 122 women (52%) were menopausal and 65 were receiving HRT. 61 (24%) women with moderate/severe fibrosis (F2–F4, Metavir score) had a longer known duration of infection (>15 years), a higher body mass index and presented with steatosis more frequently than 190 (76%) women with mild fibrosis (F0–F1). Women with F2–F4 were more often menopausal (67% v 47%). The probability of fibrosis F2–F4 was lower for menopausal women receiving HRT (p = 0.012). Steatosis was more frequent and more severe in menopausal women.
Conclusions: Severity of fibrosis was associated with a longer duration of infection (>15 years), a higher body mass index, advanced steatosis and the menopause. Menopausal women receiving HRT presented with a lower stage fibrosis. These results reinforce the hypothesis of a protective role of oestrogens in the progression of fibrosis. Steatosis may be implicated in the progression of fibrosis after the menopause.
Abbreviations: BMI, body mass index; HCV, hepatitis C virus; HRT, hormone replacement therapy
Relevant Article
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
Gut 2007 56: 313.
- Full Text
- Full Text (PDF)
-
All Versions of this Article:
gut.2006.101931v1
56/3/390 most recent - Alert me when this article is cited
- Alert me if a correction is posted
- Citation Map
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
